SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October.
2024 Maxim Healthcare Virtual Summit
Date: October 15-17, 2024
Location: Virtual
Presentation: October 15, 2024, at 2:30 p.m. E.T.
Format: Fireside Presentation and 1x1 meetings
Attendance: Sign up to become an M-Vest member
The ThinkEquity Conference 2024
Dates: October 30, 2024
Location: New York, New York, Mandarin Oriental Hotel
Presentation: October 30, 2024, at 3:30 p.m. E.T.
Format: Presentation and 1x1 meetings
Webcast Link: https://wsw.com/webcast/tep25/clnn/1673136
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors This email address is being protected from spambots. You need JavaScript enabled to view it. 617-283-2856 |
| Last Trade: | US$4.48 |
| Daily Change: | 0.24 5.66 |
| Daily Volume: | 269,471 |
| Market Cap: | US$40.230M |
August 05, 2025 June 09, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
